Katja Weisel1, Meletios Dimopoulos2, Kevin W Song3, Philippe Moreau4, Antonio Palumbo5, Andrew Belch6, Stephen Schey7, Pieter Sonneveld8, Lars Sternas9, Xin Yu9, Ramesh Amatya10, Craig J Gibson9, Mohamed Zaki9, Christian Jacques9, Jesus San Miguel11. 1. University Hospital Tübingen, Tübingen, Germany. Electronic address: katja.weisel@med.uni-tuebingen.de. 2. Alexandra Hospital, Athens, Greece. 3. Vancouver General Hospital, Vancouver, BC, Canada. 4. University Hospital Hotel-Dieu, Nantes, France. 5. University Hospital and Health City of Science of Torino, Torino, Italy. 6. University of Alberta, Edmonton, Canada. 7. King's College Hospital and King's College London, London, UK. 8. Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands. 9. Celgene Corporation, Summit, NJ. 10. Adelphi Values, Boston, MA. 11. Hospital Universitario de Salamanca, Salamanca, Spain.
Abstract
BACKGROUND:Health-related quality of life (HRQoL) is an important element for consideration in treatment decisions in patients with relapsed/refractory multiple myeloma (RRMM). The pivotal MM-003 (A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone vs. High-Dose Dexamethasone in Patients With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study [NIMBUS]) randomized, open-label, multicenter, phase III trial demonstrated improved progression-free survival (PFS) and prolonged overall survival (OS) with pomalidomide (POM) plus low-dose dexamethasone (POM + LoDEX) versus high-dose dexamethasone (HiDEX) in patients with RRMM in whom lenalidomide (LEN) and bortezomib (BORT) had failed. MM-003 also investigated HRQoL as a predefined secondary end point. PATIENTS AND METHODS: Recruited patients (n = 455) were refractory to their last treatment and had failed LEN and BORT after ≥ 2 consecutive cycles of each (alone or in combination). Eight clinically relevant and validated HRQoL domains from the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30, EORTC QLQ-MY20, and EQ-5D questionnaires were selected for analysis. Time to symptom worsening based on minimally important differences (MIDs) was calculated. RESULTS: Clinically meaningful improvements in HRQoL as determined by MIDs, regression analyses, and best response analyses were observed more frequently in patients receiving POM + LoDEX than in those receiving HiDEX. POM + LoDEX significantly extended median time to clinically meaningful worsening in HRQoL versus HiDEX in 4 HRQoL domains and demonstrated a trend in an additional 3 domains. Patients in the HiDEX arm experienced earlier HRQoL deterioration compared with those in the POM + LoDEX arm in each domain analyzed. CONCLUSION:POM + LoDEX offer good clinical outcomes that lead to improved and prolonged HRQoL compared with HiDEX in patients with RRMM and end-stage disease.
RCT Entities:
BACKGROUND: Health-related quality of life (HRQoL) is an important element for consideration in treatment decisions in patients with relapsed/refractory multiple myeloma (RRMM). The pivotal MM-003 (A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone vs. High-Dose Dexamethasone in Patients With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study [NIMBUS]) randomized, open-label, multicenter, phase III trial demonstrated improved progression-free survival (PFS) and prolonged overall survival (OS) with pomalidomide (POM) plus low-dose dexamethasone (POM + LoDEX) versus high-dose dexamethasone (HiDEX) in patients with RRMM in whom lenalidomide (LEN) and bortezomib (BORT) had failed. MM-003 also investigated HRQoL as a predefined secondary end point. PATIENTS AND METHODS: Recruited patients (n = 455) were refractory to their last treatment and had failed LEN and BORT after ≥ 2 consecutive cycles of each (alone or in combination). Eight clinically relevant and validated HRQoL domains from the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30, EORTC QLQ-MY20, and EQ-5D questionnaires were selected for analysis. Time to symptom worsening based on minimally important differences (MIDs) was calculated. RESULTS: Clinically meaningful improvements in HRQoL as determined by MIDs, regression analyses, and best response analyses were observed more frequently in patients receiving POM + LoDEX than in those receiving HiDEX. POM + LoDEX significantly extended median time to clinically meaningful worsening in HRQoL versus HiDEX in 4 HRQoL domains and demonstrated a trend in an additional 3 domains. Patients in the HiDEX arm experienced earlier HRQoL deterioration compared with those in the POM + LoDEX arm in each domain analyzed. CONCLUSION: POM + LoDEX offer good clinical outcomes that lead to improved and prolonged HRQoL compared with HiDEX in patients with RRMM and end-stage disease.
Authors: Matthew R LeBlanc; Rachel Hirschey; Ashley Leak Bryant; Thomas W LeBlanc; Sophia K Smith Journal: Qual Life Res Date: 2019-12-17 Impact factor: 4.147
Authors: Francesco Sparano; Michele Cavo; Pasquale Niscola; Tommaso Caravita; Fabio Efficace Journal: Support Care Cancer Date: 2018-03-20 Impact factor: 3.603
Authors: S Ailawadhi; J R Mikhael; B R LaPlant; K M Laumann; S Kumar; V Roy; D Dingli; P L Bergsagel; F K Buadi; S V Rajkumar; R Fonseca; M A Gertz; P Kapoor; T Sher; S R Hayman; A K Stewart; A Dispenzieri; R A Kyle; W I Gonsalves; C B Reeder; Y Lin; R S Go; N Leung; T Kourelis; J A Lust; S J Russell; A A Chanan-Khan; M Q Lacy Journal: Leukemia Date: 2017-09-01 Impact factor: 11.528
Authors: Meletios A Dimopoulos; Antonio Palumbo; Paolo Corradini; Michele Cavo; Michel Delforge; Francesco Di Raimondo; Katja C Weisel; Albert Oriol; Markus Hansson; Angelo Vacca; María Jesús Blanchard; Hartmut Goldschmidt; Chantal Doyen; Martin Kaiser; Mario Petrini; Pekka Anttila; Anna Maria Cafro; Reinier Raymakers; Jesus San-Miguel; Felipe de Arriba; Stefan Knop; Christoph Röllig; Enrique M Ocio; Gareth Morgan; Neil Miller; Mathew Simcock; Teresa Peluso; Jennifer Herring; Lars Sternas; Mohamed H Zaki; Philippe Moreau Journal: Blood Date: 2016-05-25 Impact factor: 22.113
Authors: Tobias Dechow; Ali Aldaoud; Timo Behlendorf; Wolfgang Knauf; Henning Eschenburg; Matthias Groschek; Richard Hansen; Ulrike Söling; Sina Grebhardt; Hans Ulrich Siebenbach; Corinne Vannier; Karin Potthoff Journal: Eur J Haematol Date: 2021-11-15 Impact factor: 3.674
Authors: Paul G Richardson; Jesus F San Miguel; Philippe Moreau; Roman Hajek; Meletios A Dimopoulos; Jacob P Laubach; Antonio Palumbo; Katarina Luptakova; Dorothy Romanus; Tomas Skacel; Shaji K Kumar; Kenneth C Anderson Journal: Blood Cancer J Date: 2018-11-09 Impact factor: 11.037
Authors: Caitlin Costello; Faith E Davies; Gordon Cook; Jorge Vela-Ojeda; Jim Omel; Robert M Rifkin; Jesus Berdeja; Noemi Puig; Saad Z Usmani; Katja Weisel; Jeffrey A Zonder; Evangelos Terpos; Andrew Spencer; Xavier Leleu; Mario Boccadoro; Michael A Thompson; Dorothy Romanus; Dawn M Stull; Vania Hungria Journal: Future Oncol Date: 2019-02-28 Impact factor: 3.404